NMC
CCCC icon

Nine Masts Capital’s C4 Therapeutics CCCC Stock Holding History

Nine Masts Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,157
Closed -$37.2K – 190
2026
Q1 		$37.2K Buy
14,157
+2,685
+23% +$6.32K 0.01% 192
2025
Q4 		$21.9K Buy
+11,472
New +$27.2K ﹤0.01% 101

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nine Masts Capital's CCCC Position: Q2 2026 in Review

Nine Masts Capital sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 14,157 shares — an estimated $37.2K sold.

Nine Masts Capital first reported a position in CCCC in Q4 2025 and held it in 2 quarters. The position peaked at $37.2K in Q1 2026. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Nine Masts Capital reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nine Masts Capital sold 14,157 C4 Therapeutics shares in Q2 2026, an estimated $37.2K.
  • Nine Masts Capital first reported a position in C4 Therapeutics in Q4 2025 and held it in 2 quarters.
  • Nine Masts Capital's C4 Therapeutics position peaked at $37.2K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.